• Photonics West
  • 2018 Onsite News
  • BiOS
  • LASE
  • OPTO
  • Photonics West Exhibition
  • BiOS Expo
  • Industry Events
  • Courses
  • Hotels
  • Travel to San Francisco
  • Photonics West Sponsors
  • BiOS Expo Sponsors
  • For Authors and Presenters
  • For Chairs and Committees
  • For Photonics West Exhibitors
  • For BiOS Expo Exhibitors
Print Page
Email Page
27 - 28-January 2018
San Francisco, CA, United States

NanoHybrids Inc.

NanoHybrids Inc.
3913 Todd Ln Ste 310
Austin, TX
United States
Company Description
Featured Product: PAtrace - provides depth resolved, 3D high resolution Photoacoustic maps without sample preparation

NanoHybrids develops nanotechnology solutions that facilitate non-invasive detection, molecular profiling, and novel treatments for disease. NanoHybrids combines a clinical development pipeline with commercially available products and services to drive theranostic nanoparticle innovations across applications spanning biomedical imaging and drug delivery. Through academic and industrial partnerships, the company strives to enhance the convergence of nanotechnology and medicine.
29 November 2017
NanoHybrids Inc. Awarded NIH Grant to Advance Nanoparticle Enabled Photodynamic Therapy for Oral Cancer
Austin, TX - October 27, 2017 - NanoHybrids Inc., a privately held, nanotechnology company developing novel solutions for non-invasive detection, molecular profiling, and treatment of cancers and other diseases, announced today that it has been awarded $300,000 by the National Cancer Institute of the National Institutes of Health (NIH) through the Small Business Technology Transfer (STTR) program to enhance the therapeutic efficacy of photodynamic therapy (PDT) in oral cancers.

Collaborating with NanoHybrids on the STTR project is Dr. Srivalleesha Mallidi, Instructor at Wellman Center for Photomedicine, Massachusetts General Hospital/Harvard Medical School whose research, demonstrating PDT value for murine models of glioblastoma, oral, pancreatic and other tumors as well as clinical study of PDT’s predictive efficacy in healthy volunteers is widely referred to in the PDT field.

The joint project will involve important in vivo pre-clinical studies designed to validate the efficacy of a nano-enabled platform to raise the therapeutic index of PDT in oral cancer. The nano-enabled hybrid technology’s relevance derives from an ability to enhance potency through targeted delivery of photosensitizer in combination with reactive oxygen, and carry an imaging agent to confirm patient specific dose and site-specific impact for minimized side effects.

“The STTR grant award reinforced the promise of our approach and technology to treat solid tumors in oral cancer,” stated Ryan Deschner, Ph.D., Chief Research Officer, NanoHybrids. “The financial support of the NIH grant and the collaboration with the Wellman Center for Photomedicine will accelerate the development of our nanoparticle platform for head and neck cancer patients who desire more effective treatment.”

Current treatments have evolved little over the last decade with death rates exceeding those of melanoma and cervical cancers. Global incidence continues to rise as well, mainly due to the use of tobacco products. Conventional therapeutic approaches for oral cancer often include surgery, chemotherapy and radiation, which target the tumor bulk, but have had limited effect curbing recurrence and enhancing overall survival rates. In addition, surgery often leaves patients with several functional deficits to their jaw, mouth, and facial areas which is detrimental to overall quality of life. With a demonstration of greater therapeutic index for its nano-enabled PDT platform, NanoHybrids will take important steps to improve the outcomes for these patients.
29 November 2017
Targeted Hyperthermia Treatment Accepted for Full Characterization at the Frederick National Laboratory for Cancer Research
AUSTIN, TEXAS, July 18, 2017 – Siva Therapeutics (“Siva”) is pleased to announce that its Targeted Hyperthermia™ technology has successfully passed through the first stages of nanoparticle characterization at the Frederick National Laboratory (FNL) for Cancer Research in Frederick, Md.

FNL’s Nanotechnology Characterization Laboratory (NCL) – a partnership with the U.S. Food and Drug Administration and the National Institute of Standards and Technology – is a world leader in the characterization of therapeutic nanoparticles, which helps pave the way for regulatory review of nanotechnologies intended for cancer therapies and diagnostics.

The NCL uses a three-tiered assay cascade to thoroughly characterize each nanomaterial strategy submitted to the lab for physical and chemical attributes, in vitro biological properties, and in vivo compatibility through preclinical toxicology, pharmacology, and efficacy studies. Through an application process, NCL offers preclinical characterization services to investigators nationwide who have developed promising nanotechnology-based cancer treatments. NCL’s assay cascade takes about a year to complete.

Siva delivered a pilot-scale batch of SivaRods™ precision gold nanorods, manufactured by partner company NanoHybrids, Inc. to the NCL early in 2017. “We are pleased that our partnership with Siva continues to progress and build value for both companies,” stated Kimberly Homan, PhD,CTO of NanoHybrids. “Through the NCL process, we are building support for the clinical translation of Siva’s promising technology.”

“The NCL Assay Cascade Program is the premier program in the world for bringing nanomaterials through critical preclinical stages and facilitating regulatory review.” said Len Pagliaro, PhD, CEO of Siva. “We are very pleased at having successfully passed through the first stages of the program, a step which validates the manufacturing capabilities of our partners at NanoHybrids, Inc., and the commercial potential of SivaRods for Targeted Hyperthermia. The scientific, technical, and regulatory resources of the NCL are greatly strengthening Siva’s next steps toward the clinic.”
Search Open Calls
Enter keywords to find conferences with open calls for papers and submit an abstract.